VIS1019

VIS1019 is a preclinical-stage monoclonal antibody being developed by Visterra, a subsidiary of Otsuka Pharmaceutical, for the treatment of immune-mediated diseases. The antibody was engineered using Visterra's proprietary Hieras™ platform, which integrates computational design and structural biology to target specific epitopes on complex proteins that are often difficult to address with traditional antibody discovery methods. As of mid-2026, VIS1019 is positioned within Visterra's immunology and inflammation pipeline, although its specific molecular target and mechanism of action have not been publicly disclosed.